Overview
- A peer-reviewed systematic review published Oct. 13, 2026 in the Journal of the Endocrine Society reports people with polyendocrine metabolic ovarian syndrome (PMOS) show mild but reproducible deficits in memory, attention and executive function that align with Alzheimer’s-related brain changes.
- The authors conclude the apparent link is most consistently explained by coexisting metabolic conditions—chiefly insulin resistance and obesity—rather than by PMOS acting as an independent cause of dementia.
- The review pooled 21 clinical, imaging, biomarker and mechanistic studies published 2007–2025 that together covered roughly 75,000 participants but found the evidence limited by small, heterogeneous cohorts and inconsistent endpoints.
- Clinically, the paper does not recommend routine dementia screening for people with PMOS and instead urges active metabolic risk management while calling for well‑designed randomized trials with standardized cognitive outcomes.
- Key research gaps include long-term dementia incidence in aging PMOS cohorts, genetic and molecular overlap with Alzheimer’s biology, the role of sex hormones and the gut microbiome, and whether metabolic or PMOS-specific treatments change cognitive trajectories.